NDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
ISTALOL (timolol maleate) by Bausch + Lomb is 1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. First approved in 2004.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISTALOL is a topical ophthalmic solution containing timolol maleate, a non-selective beta-adrenergic receptor blocking agent indicated for ocular hypertension and open-angle glaucoma. It reduces intraocular pressure primarily by decreasing aqueous humor formation, with onset within 30 minutes and maximum effect in 1-2 hours. The drug maintains IOP-lowering efficacy over 24 hours with once-daily dosing.
$0.8MPart D
LOE ApproachingProduct is nearing loss of exclusivity with minimal Part D penetration ($803K), signaling limited career growth opportunity and potential team contraction.
Mechanism of Action
1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients…
Indications
Worked on ISTALOL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.